Given such tremendous body of evidence supporting STn as a key modulator of tumour growth and progression, several STn targeted therapeutics are in pre-clinical stage of development, including humanized antibodies [49–52], glycovaccines [53, 54] and glycomimetics for immunization [55, 56]. The gene discussed is EEF1A2; the disease is neoplasm.